Australia	NNP
has	VBZ
a	DT
slightly	RB
different	JJ
pregnancy	NN
category	NN
system	NN
from	IN
the	DT
United	NNP
States	NNP
-	HYPH
notably	RB
the	DT
subdivision	NN
of	IN
Category	NNP
B.	NNP

The	DT
system	NN
,	,
as	IN
outlined	VBN
below	IN
,	,
was	VBD
established	VBN
by	IN
the	DT
Congenital	NNP
Abnormalities	NNPS
Sub	NNP
-	HYPH
committee	NN
of	IN
the	DT
Australian	NNP
Drug	NNP
Evaluation	NNP
Committee	NNP
(	-LRB-
ADEC	NNP
)	-RRB-
.	.

ADEC	NNP
Pregnancy	NNP
Categories	NNP
(	-LRB-
Australia	NNP
)	-RRB-

'	``
Pregnancy	NN
Category	NNP
A	NNP
'	''

Drugs	NNS
which	WDT
have	VBP
been	VBN
taken	VBN
by	IN
a	DT
large	JJ
number	NN
of	IN
pregnant	JJ
women	NNS
and	CC
women	NNS
of	IN
childbearing	NN
age	NN
without	IN
an	DT
increase	NN
in	IN
the	DT
frequency	NN
of	IN
malformations	NNS
or	CC
other	JJ
direct	JJ
or	CC
indirect	JJ
harmful	JJ
effects	NNS
on	IN
the	DT
fetus	NN
having	VBG
been	VBN
observed	VBN
.	.

'	``
Pregnancy	NN
Category	NN
B1	NN
'	''

Drugs	NNS
which	WDT
have	VBP
been	VBN
taken	VBN
by	IN
only	RB
a	DT
limited	JJ
number	NN
of	IN
pregnant	JJ
women	NNS
and	CC
women	NNS
of	IN
childbearing	VBG
age	NN
,	,
without	IN
an	DT
increase	NN
in	IN
the	DT
frequency	NN
of	IN
malformation	NN
or	CC
other	JJ
direct	JJ
or	CC
indirect	JJ
harmful	JJ
effects	NNS
on	IN
the	DT
human	JJ
fetus	NN
having	VBG
been	VBN
observed	VBN
.	.

Studies	NNS
in	IN
animals	NNS
have	VBP
not	RB
shown	VBN
evidence	NN
of	IN
an	DT
increased	VBN
occurrence	NN
of	IN
fetal	JJ
damage	NN
.	.

'	``
Pregnancy	NN
Category	NN
B2	NN
'	''

Drugs	NNS
which	WDT
have	VBP
been	VBN
taken	VBN
by	IN
only	RB
a	DT
limited	JJ
number	NN
of	IN
pregnant	JJ
women	NNS
and	CC
women	NNS
of	IN
childbearing	VBG
age	NN
,	,
without	IN
an	DT
increase	NN
in	IN
the	DT
frequency	NN
of	IN
malformation	NN
or	CC
other	JJ
direct	JJ
or	CC
indirect	JJ
harmful	JJ
effects	NNS
on	IN
the	DT
human	JJ
fetus	NN
having	VBG
been	VBN
observed	VBN
.	.

Studies	NNS
in	IN
animals	NNS
are	VBP
inadequate	JJ
or	CC
may	MD
be	VB
lacking	VBG
,	,
but	CC
available	JJ
data	NNS
show	VBP
no	DT
evidence	NN
of	IN
an	DT
increased	VBN
occurrence	NN
of	IN
fetal	JJ
damage	NN
.	.

'	``
Pregnancy	NN
Category	NN
B3	NN
'	''

Drugs	NNS
which	WDT
have	VBP
been	VBN
taken	VBN
by	IN
only	RB
a	DT
limited	JJ
number	NN
of	IN
pregnant	JJ
women	NNS
and	CC
women	NNS
of	IN
childbearing	VBG
age	NN
,	,
without	IN
an	DT
increase	NN
in	IN
the	DT
frequency	NN
of	IN
malformation	NN
or	CC
other	JJ
direct	JJ
or	CC
indirect	JJ
harmful	JJ
effects	NNS
on	IN
the	DT
human	JJ
fetus	NN
having	VBG
been	VBN
observed	VBN
.	.

Studies	NNS
in	IN
animals	NNS
have	VBP
shown	VBN
evidence	NN
of	IN
an	DT
increased	VBN
occurrence	NN
of	IN
fetal	JJ
damage	NN
,	,
the	DT
significance	NN
of	IN
which	WDT
is	VBZ
considered	VBN
uncertain	JJ
in	IN
humans	NNS
.	.

'	``
Pregnancy	NN
Category	NN
C	NNP

'	``
Drugs	NNS
which	WDT
,	,
owing	VBG
to	IN
their	PRP$
pharmaceutical	JJ
effects	NNS
,	,
have	VBP
caused	VBN
or	CC
may	MD
be	VB
suspected	VBN
of	IN
causing	VBG
,	,
harmful	JJ
effects	NNS
on	IN
the	DT
human	JJ
fetus	NN
or	CC
neonate	NN
without	IN
causing	VBG
malformations	NNS
.	.

These	DT
effects	NNS
may	MD
be	VB
reversible	JJ
.	.

'	``
Pregnancy	NN
Category	NN
D	NN
'	''

Drugs	NNS
which	WDT
have	VBP
caused	VBN
,	,
are	VBP
suspected	VBN
to	TO
have	VB
caused	VBN
or	CC
may	MD
be	VB
expected	VBN
to	TO
cause	VB
,	,
an	DT
increased	VBN
incidence	NN
of	IN
human	JJ
fetal	JJ
malformations	NNS
or	CC
irreversible	JJ
damage	NN
.	.

These	DT
drugs	NNS
may	MD
also	RB
have	VB
adverse	JJ
pharmacological	JJ
effects	NNS
.	.
'	''

